Document:

<PAGE>   1
                                       [***] - CONFIDENTIAL TREATMENT REQUESTED

                                                                   EXHIBIT 10.9

                         CONFIDENTIAL TREATMENT REQUEST

         Confidential Portions Of This Agreement Which Have Been Redacted Are
Marked With Brackets ("[***]"). The Omitted Material Has Been Filed Separately
With The Securities And Exchange Commission.

                      HORIZON PHARMACEUTICAL & INPHARMAKON
                            COLLABORATION AGREEMENT

THIS AGREEMENT made as of the 31st day of October, 1998 ("Effective Date")
between Horizon Pharmaceutical Corporation, a Delaware corporation of 660
Hembree Parkway, Suite 106, Roswell, Georgia 30076 ("Horizon") and InpharmaKon
Corporation, a Delaware corporation of 191 Waukegan Road, Suite 206,
Northfield, Illinois 60099 ("Inpharmakon").

                                   RECITALS:

         A. Horizon is a pharmaceutical product development and marketing
company;

         B. Inpharmakon is in the business of developing and assembling
literature based product registration packages for the purpose of enabling
marketing partners to file NDAs (defined below) with the FDA (defined below)
for marketing approval of off label indications for FDA approved pharmaceutical
products.

         C. Horizon wishes to collaborate with Inpharmakon and Inpharmakon
wishes to collaborate with Horizon for the purpose of preparing a NDA for
submission by Horizon to the FDA requesting approval to market [***] for the
indicated use of migraine prophylaxis on the following terms and conditions.

         NOW, THEREFORE, the parties agree as follows:

                                   ARTICLE I
                                  DEFINITIONS

         In this Agreement the following expressions shall have the meaning set
forth in this Article.

         1.01 ACCOUNTING PERIOD. The term "Accounting Period" means a calendar
quarter.

         1.02 AFFILIATE. The term "Affiliate" means a corporation or business
entity which, directly or indirectly, is controlled by one of the parties or
controls one of the parties. For this purpose, the meaning of the word
"control" shall include, but not be limited to, ownership of fifty percent
(50%) or more of the voting shares or interest of such corporation or business
entity.

                                       1
<PAGE>   2
                                        [***] - CONFIDENTIAL TREATMENT REQUESTED

         1.03 ANDA. The term "ANDA" means an Abbreviated New Drug Application.

         1.04 CLINICAL TRIALS. The term "Clinical Trials" refers to the
clinical trials which Horizon is required to perform under Section 3.01 (ii)
below.

         1.05 CONFIDENTIAL INFORMATION. The term "Confidential Information" is
defined in Article VII below.

         1.06 FDA. The term "FDA" means the United States Food and Drug
Administration.

         1.07 FIRST COMMERCIAL SALE. The term "First Commercial Sale" means the
first sale of the Product to a third party purchaser after NDA approval of the
Product for the Indication.

         1.08 FORMULATION. The term "Formulation" is defined in Section 3.01(i)
below.

         1.09 HORIZON AFFILIATE. The term "Horizon Affiliate" means an
Affiliate of Horizon.

         1.10 INDICATION. The term "Indication" means the indication for
migraine prophylaxis.

         1.11 INPHARMAKON AFFILIATE. The term "Inpharmakon Affiliate" means an
Affiliate of Inpharmakon.

         1.12 NDA. The term "NDA" means a New Drug Application submitted to the
FDA requesting approval to market the Product for the Indication.

         1.13 NET SALES. The term "Net Sales" means the gross invoice price of
all Product using the Formulation actually billed by Horizon, Horizon
Affiliates or sublicensees and their Affiliates to unrelated third party
customers less (i) any direct or indirect credits and allowances or adjustments
granted to such customers, including, without limitation, credits and
allowances on account of price adjustments or on account of rejection or return
of Product previously sold, (ii) any trade and cash discounts, and rebates,
(iii) any sales, excise, turnover and similar taxes, and any duties and other
governmental charges imposed upon the production, use or sale of Product or
partly processed Product, and (iv) transportation, insurance and other handling
charges provided that such charges can be reasonably allocated to such billings
and are not separately invoiced.

         1.14 OPPORTUNITY PACKAGE. The term "Opportunity Package" means the
existing opportunity package already delivered to Horizon, receipt of which is
hereby acknowledged, which describes the Product, the targeted indication, and
an overview of its off label usage and was based upon a review of the published
clinical data for the Product and a patent search to establish prima facie
feasibility.

         1.15 PRODUCT. The term "Product" means [***].

                                       2
<PAGE>   3

         1.16     SUBLICENSE. The term "Sublicense" is defined in Section 4.02
below.

                                   ARTICLE II
                                 COLLABORATION

         2.01     SCOPE. Horizon shall work to obtain NDA registration for and
commercialization of the Product indicated for the Indication. Horizon shall
develop a once a day proprietary formulation for the Product and have primary
responsibility for clinical, formulation, manufacturing, and regulatory issues,
and preparation of the NDA for the Product for the Indication.

         2.02.    OPPORTUNITY PACKAGE. Inpharmakon shall give Horizon the
exclusive right to use the Opportunity Package for the purposes of preparing
and filing a NDA for the Product with the FDA for the Indication. Subject to
Inpharmakon's rights upon termination under Article IX below, with effect from
the Effective Date, Inpharmakon shall assert against Horizon no claim to the
ownership of the following intellectual property related to the Product (i) the
Formulation developed by or for Horizon under Section 3.01(i) below, or (ii)
the data arising from the Clinical Trials, nor to the rights to sales,
marketing and distribution for the Product for the Indication. After Horizon
has contracted with a formulator to develop the Formulation, Horizon shall have
the right and power to sublicense its exclusive rights to use the Opportunity
Package.

         2.03     SUBLICENSES. In the event Horizon enters into any Sublicenses,
Horizon shall provide Inpharmakon with a copy of each such Sublicense within 10
days of its execution.

                                  ARTICLE III
                        RESPONSIBILITIES OF THE PARTIES

         3.01.    RESPONSIBILITIES OF HORIZON. Horizon's responsibilities are as
follows:

         i)       To develop or have developed for it a workable once a day
                  formulation (the "Formulation") for the Product or, with
                  Inpharmakon's consent which consent will not be unreasonably
                  withheld, substitute another formulation (also referred to as
                  the "Formulation") with strong marketable differences over
                  available generic formulations of the Product;

         ii)      To conduct such clinical trials ("Clinical Trials") as may be
                  necessary to prepare and file a NDA for the Product using the
                  Formulation and indicated for the Indication; and

         iii)     To prepare and file with the FDA a NDA registration package
                  for the Product using the Formulation indicated for migraine
                  prophylaxis, and exert all reasonable efforts to obtain
                  approval of the NDA and commercialize the Product in the
                  United States of America.

                                       3
<PAGE>   4

         3.02     LICENSE OF FORMULATION. In the event Horizon licenses the
Formulation from a third party, Horizon shall ensure that the license permits
Horizon to assign its interest in the Formulation to Inpharmakon should
Inpharmakon exercise its rights to assume Horizon's rights to the Formulation
under Sections 9.01 and 9.02 below.

         3.03     RESPONSIBILITIES OF INPHARMAKON: Inpharmakon's
responsibilities are to provide Horizon with the following services:

         i)       To deliver the Opportunity Package to Horizon plus, at no
                  additional cost to Horizon, provide additional review of such
                  published clinical trials not found in the Opportunity
                  Package as the FDA may require after its initial review of
                  the NDA for the Indication;

         ii)      To cooperate with and assist Horizon to design, conduct, and
                  evaluate the Clinical Trials using the Formulation for the
                  purpose of establishing safety and efficacy for the Product
                  indicated for the Indication;

         iii)     To cooperate with and assist Horizon to assemble the NDA for
                  the Product indicated for the Indication, including assembly
                  of published clinical literature and summaries;

         iv)      To assist and advise Horizon concerning follow-up information
                  required by the FDA in support of the NDA, including
                  attendance at meetings with the FDA; and

         v)       Provide other reasonable services as may be agreed by the
                  parties in support of Horizon's efforts to obtain approval of
                  the NDA for the Product for the Indication.

         3.04     FDA REGULATORY SUPPORT. In the event that Horizon requires
support with regard to its activities regulated by the FDA over and above
Inpharmakon's services under Section 3.03(ii) through iv) above, Inpharmakon or
an Inpharmakon Affiliate shall provide reasonable support requested by Horizon.
Such support shall be free of charge during the first 8 months of the term of
this Agreement. Thereafter Inpharmakon shall charge Horizon at the provider's
(Inpharmakon's or the Inpharmakon Affiliate's) regular rates presently $120 per
hour and Horizon shall pay such charges within 30 days of the invoice date.

         3.05     INPHARMAKON EXPENSES. Horizon shall reimburse Inpharmakon for
Inpharmakon's documented out of pocket travel expenses related to the
performance of its responsibilities under Section 3.03(ii) through (v) above.
Horizon shall make such reimbursements within 30 days of the invoice date.

                                       4
<PAGE>   5

                                   ARTICLE IV
                                  COMPENSATION

         4.01     FEES AND ROYALTIES. Horizon shall pay to Inpharmakon as
compensation for its services:

         i)       $200,000.00 within 30 days after the Effective Date;

         ii)      $100,000.00 within 30 days after filing the NDA for the
                  Product for the Indication

         iii)     $400,000.00 within 30 days after approval of such NDA; and

         iv)      A royalty of 5% of the Net Sales by Horizon or Horizon
                  Affiliates payable 45 days after the end of each Accounting
                  Period on all sales of the Product using the Formulation for
                  so long as Horizon or a Horizon Affiliate sell the Product.

Under no circumstances shall payments received by Inpharmakon under paragraphs
(i) through (iii) of this Section be refundable in whole or in part.

         4.02     SUBLICENSES. In the event that Horizon grants any third party
a sublicense or other rights (together referred to as a "Sublicense") to make,
have made, use, import, market or sell the Product for the Indication, Horizon
shall pay to Inpharmakon the following royalties:

         i)       If a Sublicense is granted after Horizon enters into a
                  contract for development of the Formulation, 50% of the
                  consideration (cash and in kind) other than royalties under
                  paragraph (v) of this Section received by Horizon less costs
                  incurred by Horizon on behalf of the sublicensee and
                  reimbursed by the sublicensee;

         ii)      If a Sublicense is granted after development of the
                  Formulation has been completed, 33% of the consideration
                  (cash and in kind) other than royalties under paragraph (v)
                  of this Section received by Horizon less costs incurred by
                  Horizon on behalf of the sublicensee and reimbursed by the
                  sublicensee;

         iii)     If a Sublicense is granted after completion of the Clinical
                  Trials, 25% of the consideration (cash and in kind) other
                  than royalties under paragraph (v) of this Section received
                  by Horizon less costs incurred by Horizon on behalf of the
                  sublicensee and reimbursed by the sublicensee; or

         iv)      If a Sublicense is granted after approval of the NDA for the
                  Product indicated for the Indication, 20% of the
                  consideration (cash and in kind) other than royalties under
                  paragraph (v) of this Section received by Horizon less costs
                  incurred by Horizon on behalf of the sublicensee and
                  reimbursed by the sublicensee; and

                                       5
<PAGE>   6
                                        [***] - CONFIDENTIAL TREATMENT REQUESTED

         v)       With effect from the First Commercial Sale, 5% of Net Sales
                  by sublicencees and their Affiliates.

         4.03     NO RELEASE OF SECTION 4.01 PAYMENTS. The grant of Sublicenses
by Horizon shall not release Horizon from its obligations to make the payments
required by Section 4.01(i) through (iii) above.

         4.04     OTHER INDICATIONS. Provided that Horizon has paid all of the
payments required by Section 4.01(i) through (iii) above, Horizon shall have
the right to prepare and file ANDAs and NDAs for the Product for indications
other than the Indication. In that event the following provisions shall apply:

         i)       If Product sold by Horizon or Horizon Affiliates for such
                  indications use the Formulation, Horizon shall pay to
                  Inpharmakon the royalties as provided under Section 4.01(iv)
                  above.

         ii)      If Product sold by Horizon or Horizon Affiliates for such
                  indications does not use the Formulation (i.e. it uses
                  another formulation useful in the therapeutic range for
                  migraine prophylaxis which improves on generically available
                  formulations for the Product) but the Product is prescribed
                  for migraine prophylaxis, Horizon shall pay to Inpharmakon
                  the royalties as provided under Section 4.01(iv) above on all
                  such sales of the Product for such prescriptions.

         iii)     Horizon shall pay to Inpharmakon the royalties provided under
                  Section 4.02(v) on all sales of Product by sublicensees and
                  their Affiliates which, if made by Horizon, would be subject
                  to royalty payments under paragraphs (i) or ii) of this
                  Section.

         iv)      No royalties shall be due or payable on the Product for such
                  indications where the Product uses a formulation that is
                  neither useful in the therapeutic range of migraine
                  prophylaxis nor a formulation which improves on generically
                  available formulations for the Product, and the formulation
                  is not prescribed for migraine prophylaxis.

For the purposes of paragraphs (ii) and (iv) of this Section the term
"improves" refers to a technical or non-technical difference in the formulation
not found in generically available formulations for the Product which
difference differentiates the Product from other [***] products (using either
the Formulation or a generically available formulation) for marketing purposes.

                                       6
<PAGE>   7

                                   ARTICLE V
                                CLINICAL TRIALS

         For the purposes of Section 3.01(ii) above, Horizon shall contract
with LAB Biosyn of Montreal, Canada or another clinical research organization
to perform clinical trials the same as or equivalent to (1) the program
prepared by LAB Biosyn, a copy of which Inpharmakon shall provide to Horizon
contemporaneously with the execution of this Agreement, or (2) that recommended
by the FDA.

                                   ARTICLE VI
                          PAYMENT OF ROYALTIES; AUDIT

         6.01 PAYMENT OF ROYALTIES. Horizon shall remit all royalty payments to
Inpharmakon no later than 45 days after the close of each Accounting Period.
Each royalty payment shall be accompanied by a report of the Net Sales subject
to royalty during the Accounting Period. Horizon will deduct withholding taxes
from payments to Inpharmakon only if required by applicable law.

         6.02     AUDIT RIGHTS.  The following provisions shall apply:

         (i)      Inpharmakon, at its own expense, shall have the right, upon
                  reasonable prior notice, but no more than once in any year,
                  to appoint independent auditors and have them during normal
                  business hours, inspect and copy the books and accounts of
                  Horizon, Horizon Affiliates and Horizon's sublicensees, if
                  any, related to the payment and calculation of royalties
                  arising under this Agreement. Horizon shall cooperate and
                  cause Horizon Affiliates and sublicensees, if any, to
                  cooperate with such auditors. The auditors performing the
                  audit shall disclose to Inpharmakon only information relating
                  to the accuracy of records kept and the payments made, and
                  shall be under a duty to keep confidential any other
                  information obtained from such records.

         (ii)     If any such audit establishes that Horizon has underpaid or
                  overpaid the amount due, Horizon shall promptly pay any
                  remaining amounts due as established by such audit or, in the
                  event of an overpayment, Inpharmakon shall promptly refund any
                  such over payment. If the underpayment is by 5% or more during
                  any Accounting Period, Horizon shall reimburse Inpharmakon for
                  its out of pocket expense of such audit, and shall pay to
                  Inpharmakon interest on the amount of the underpayment at a
                  rate of 3% above the official prime rate, as announced from
                  time to time by Citibank NA, New York, or at such lower rate
                  as shall then be the maximum rate permitted by law that may be
                  charged on any such overdue payment from the date due until
                  paid.

                                       7
<PAGE>   8

                                  ARTICLE VII
                                CONFIDENTIALITY

         For a period of 5 years after first disclosure, the parties shall keep
completely confidential, shall not publish or otherwise disclose, and shall not
use for any purpose other than the purposes contemplated by this Agreement, any
Confidential Information without the consent of the disclosing party first had
and obtained. The term "Confidential Information" is that information furnished
by either party to the other in writing and marked "Confidential", or if first
disclosed orally, disclosed in writing and marked "Confidential" within 30 days
after first disclosure. Confidential Information shall not include information
that the receiving party can establish by competent proof:

         (i)      was already  known to it prior to disclosure by the disclosing
                  party as evidenced by written record or other proof;

         (ii)     was or becomes public knowledge through no fault of the
                  receiving party;

         (iii)    has been received from a third party who did not acquire it
                  directly or indirectly from the disclosing party;

         (iv)     is independently developed by the receiving party without
                  reference to any Confidential Information received from the
                  disclosing party under this Agreement; or

         (v)      is compelled to be disclosed in the course of litigation with
                  a third party, provided that the compelled party provides the
                  disclosing party with notice of such compulsion sufficiently
                  in advance of disclosure so as to provide the disclosing
                  party with a reasonable time period to seek a protective
                  order.

Notwithstanding the above, the parties may disclose such Confidential
Information to their legal representatives and employees, and to consultants,
to the extent such disclosure is reasonably necessary to achieve the purposes
of this Agreement, obtaining an NDA for the Product for the Indication, and
provided such representatives, employees, and consultants are covered by
obligations of confidentiality with respect to such information no less
stringent than those set forth above.

                                  ARTICLE VIII
                              TERM AND TERMINATION

         8.01 TERM. The term of this Agreement shall commence on the Effective
Date and shall continue for a period of 10 years thereafter, with automatic
renewal for successive 5 year terms for so long as Inpharmakon, Horizon, and
their respective Affiliates are in substantial compliance with the terms of
this Agreement, unless otherwise terminated earlier pursuant to this Article
VIII.

                                       8
<PAGE>   9

         8.02     TERMINATION FOR MATERIAL BREACH. Either party may terminate
this Agreement in the event the other party materially breaches in the
performance of its obligations under this Agreement, and such breach continues
for 90 days after written notice specifying the breach was provided to the
breaching party by the non-breaching party. Any such termination shall become
effective at the end of such 90 day period unless the breaching party (or any
other party on its behalf) has cured any such breach prior to the expiration of
the 90 day period. A material breach is (i) the assertion of ownership rights
by Inpharmakon in violation of Section 2.02, (ii) the failure by either party
to perform in a timely manner the respective obligations and responsibilities
of the parties under Article III above, (iii) the failure by Horizon to pay the
compensation due under Article IV above, or (iv) the breach by either party of
the confidentiality provisions of Article VII above.

         8.03     BANKRUPTCY. Either party may terminate this Agreement upon the
filing or institution of bankruptcy, reorganization, liquidation or
receivership proceedings, or upon an assignment of substantially all of the
assets for the benefit of creditors by the other party; provided, however, in
the case of an involuntary bankruptcy proceeding such right to terminate shall
only become effective if the party consents to the involuntary bankruptcy or
such proceeding is not dismissed within 90 days after the filing thereof.

         8.04     TERMINATION BY INPHARMAKON. Inpharmakon shall have the right
to terminate this Agreement on notice to Horizon in the event of:

         (i)      The failure of Horizon, within 4 months after the Effective
                  Date to acquire or authorize a formulator to develop a
                  workable once a day formulation for the Product.

         (ii)     The failure of Horizon, within 12 months after the Effective
                  Date to complete, in connection with the development of the
                  Formulation, all necessary in-vitro clinical studies and
                  complete a clinical bioavailability study in a small group of
                  at least 8 patients, provided that in the event that
                  technical difficulties with such study are encountered, such
                  12 month period will be extended by 3 months to 15 months if
                  the bioavailability study was initiated within such 12 month
                  period.

         (iii)    The failure of Horizon, within 6 months after completing the
                  clinical bio-availability study on the Formulation under
                  paragraph (ii) above, to authorize or initiate the Clinical
                  Trials.

         (iv)     The failure of Horizon to file the NDA within 8 months after
                  completion of the Clinical Trials, including the full
                  statistical analyses.

         (v)      The failure of the FDA within 3 years of the filing date of
                  the NDA for the Product for the Indication, to approve the
                  NDA unless the FDA is holding up approval pending agreement
                  on labeling requirements for the Formulation, in which case
                  the period will be 4 years;

                                       9
<PAGE>   10

                                          [***] CONFIDENTIAL TREATMENT REQUESTED

         (vi)     The failure of Horizon to make the First Commercial Sale
                  within 6 months after receipt of the NDA approval for the
                  Product for the Indication, and to thereafter aggressively
                  market and sell the Product for the Indication.

         Should Horizon have informed Inpharmakon in due time of serious
         reasons for the delay in the achievement of the events under
         paragraphs (iii), (iv) or (v) above, the parties shall negotiate in
         good faith an extension or extensions of time for Horizon to complete
         the event delayed without Inpharmakon exercising its termination
         rights provided that such serious reasons do not delay the
         commercialization of the Product beyond 5 years after the Effective
         Date. Any waiver by Inpharmakon in one instance shall not obligate
         Inpharmakon to grant any additional or other waivers of Horizon's
         obligations.

                                   ARTICLE IX
                          CONSEQUENCES OF TERMINATION

         9.01 DEFAULT OF HORIZON. If this Agreement is terminated for failure
of Horizon to pay any of the Article IV payments, or is terminated under
Section 8.04(i) through (iv) and no default of Inpharmakon was the primary
cause of the default, Inpharmakon shall have the exclusive right to proceed
with a NDA for the Product for the Indication using the Formulation and the
data from the Clinical Trials as has been acquired or developed by Horizon at
the date of termination, and shall have the right to assume Horizon's rights to
the same and the NDA, if applicable, without cost to Inpharmakon or Inpharmakon
Affiliates. In that event Horizon shall release to Inpharmakon its rights to
the Opportunity Package, the Formulation, the related not publicly available
information provided by Inpharmakon or developed by or for Horizon, and
registration data related to the NDA for the Product for the Indication.

         9.02 FAILURE TO COMMERCIALIZE. If this Agreement is terminated under
Section 8.04(vi) for failure to commercialize the Product for the Indication,
Inpharmakon shall have the exclusive option to purchase Horizon's rights to the
Formulation and the NDA for the Product for the Indication, if applicable, and
the exclusive right to use the data from the Clinical Trials, all for a price
equal to Horizon's booked costs incurred to obtain the same. In that event,
Inpharmakon shall have the right to proceed with a NDA for the Product for the
Indication by itself or through others.

         9.03 NO FAULT TERMINATION. If this Agreement is terminated under
Section 8.04(v) Horizon shall have the right to proceed with an ANDA or NDA
with any formulation of [***] for any indication, including hypertension,
without further obligation to Inpharmakon, including but not limited to no
obligation to pay royalties on Net Sales of any and all formulations of the
Product. In that event Inpharmakon shall have an option to purchase Horizon's
rights to the Formulation and the data from the Clinical Trials at Horizon's
booked costs incurred to obtain the same, but only for the Indication.

                                      10
<PAGE>   11

                                          [***] CONFIDENTIAL TREATMENT REQUESTED

         9.04 CONDITIONS TO INPHARMAKON RIGHTS. Inpharmakon's rights under
Sections 9.01 and 9.02 above are conditioned upon the termination not arising
primarily from problems with the Opportunity Package or Inpharmakon's
regulatory support under Section 3.03ii) or iv). If the termination is as a
result of such problems Inpharmakon shall have no rights to the Formulation or
the data from the Clinical Trials. However, should Inpharmakon so request and
have informed Horizon in due time the reasons for the problems, the parties
shall negotiate in good faith an extension or extensions of time for
Inpharmakon to repair or cure the problems without Horizon exercising its
termination rights hereunder. Any waiver by Horizon in one instance shall not
obligate Horizon to grant additional or other waivers of Inpharmakon's
obligations.

         9.05 NO RELEASE OF PRIOR OBLIGATIONS. Termination of this Agreement
for any reason shall not release either party from any liability which, at the
time of such termination, has already accrued to the other party or which is
attributable to a period prior to such termination nor preclude either party
from pursuing all rights and remedies it may have under this Agreement or at
law or in equity with respect to any breach of the Agreement.

         9.06 SURVIVAL OF TERMS. Articles IV, VI, VII, X, XI, XII and XIII, and
Sections 3.02 and 9.01 through 9.05 shall survive the expiration or termination
of this Agreement for any reason.

                                   ARTICLE X
            REPRESENTATIONS & WARRANTIES, DISCLAIMERS & INDEMNITIES

         10.01 REPRESENTATIONS & WARRANTIES.

               (a) Horizon warrants and represents to Inpharmakon that it has or
prior to commercialization will have the right to manufacture, market and sell
[***], and that such manufacturing, marketing and sale will not infringe the
rights of any third parties.

               (b) Inpharmakon warrants and represents that it has evaluated
and, to the best of its knowledge and belief, accurately reported all clinical
information, including safety and efficacy data, ft has included in the
Opportunity Package.

         10.02 INPHARMAKON DISCLAIMER. Inpharmakon specifically disclaims any
guarantee that the NDA for the Product for the Indication will be successful,
in whole or in part. Inpharmakon will evaluate and accurately report all
clinical information, including safety and efficacy data, it includes in the
literature package for the NDA, but expressly disclaims any responsibility to
independently verify such information for accuracy or completeness. Further,
Inpharmakon expressly disclaims any responsibility for independently verifying
that such clinical information pulled from publicly available or commercial
sources does not infringe third party proprietary rights. However, Inpharmakon
has and will exercise reasonable judgment in deciding whether or not such
information should be used in the NDA. Inpharmakon expressly disclaims
responsibility for the scientific methodologies, clinical protocols and results
obtained and reported in the published literature.

                                      11
<PAGE>   12

         10.03. INDEMNIFICATION. Horizon shall indemnify, defend and hold
Inpharmakon harmless from and against all product liability claims, actions,
suits and other proceedings, and related costs, including legal fees and
expenses, liabilities, damages and other expenses arising from (i) Horizon's
use of the scientific methodologies, clinical protocols and results referenced
in Section 10.02 above and (ii) the manufacture and sale of the Product. In
addition, in the event of any claims, actions, suits or other proceedings
alleging that Horizon's use, manufacture, marketing or sale of the Product
infringes the rights of third parties, Horizon shall indemnify, defend and hold
Inpharmakon harmless from and against all such claims, actions, suits or other
proceedings, and related costs, including legal fees and expenses, liabilities,
damages, and other expenses incurred by Inpharmakon arising therefrom. Horizon
shall not be obligated to indemnify Inpharmakon as aforesaid unless Inpharmakon
promptly notifies Horizon of the claim, action, suit, or other proceeding and
Inpharmakon thereafter cooperates with and assists Horizon, at Horizon's
expense, in the defense of such claim, action, suit or other proceeding.

                                   ARTICLE XI
                                    NOTICES

         All information, reports, notices and other communications under this
Agreement will be in writing. Such information, reports, notices and other
communications, and payments will be deemed given to a party when sent to such
party by certified or registered mail, return receipt requested, postage
prepaid; by hand; by facsimile, receipt confirmed; or by overnight courier
which provides confirmation of delivery, at the appropriate address set forth
above. Either party may change its address for the giving of notice by written
notice to the other party as set forth above.

                                  ARTICLE XII
                                  ARBITRATION

         Any dispute arising out of the interpretation or performance of this
Agreement or the breach thereof, shall be submitted to arbitration in Chicago,
Illinois in accordance with the Commercial Rules of the American Arbitration
Association. The arbitration award shall be final and binding on the parties.
The arbitrators' fees shall be borne by the losing party. If both parties are
found liable, the arbitrators' fees shall be borne in proportion to the extent
to which each party is found liable. In the event either party is forced to
take legal action in order to enforce an arbitral award hereunder, the
defending party shall pay the claimant party's costs and expenses, including
reasonable attorney fees and expenses, incurred to enforce such arbitral award.

                                  ARTICLE XIII
                                 MISCELLANEOUS

                                      12
<PAGE>   13

         13.01 INDEPENDENT CONTRACTORS. The relationship of the parties is that
of independent contractors. The parties are not deemed to be agents, partners
or joint venturers with the other for any purpose as a result of this Agreement
or the transactions contemplated thereby.

         13.02 AMENDMENT. This Agreement may not be amended, supplemented, or
otherwise modified except by an instrument in writing signed by both parties.

         13.03 ENTIRE AGREEMENT. This Agreement constitutes the entire
agreement and understanding of the parries relating to the subject matter of
this Agreement. It supersedes all previous communications, proposals,
representations and agreements (including the Confidential Disclosure Agreement
dated June 25, 1998 and the Term Sheet dated October 13, 1998 between the
parties), whether oral or written, relating to the subject matter of this
Agreement.

         13.04 SEVERANCE. Should any provision of this Agreement be determined
by a court of competent jurisdiction to violate or contravene any applicable
law or policy, such provision shall be severed or modified to the extent
necessary to comply with the applicable law or policy, and such modified
provision and the remainder of the provisions hereof will continue in full
force and effect.

         13.05 GOVERNING LAW. This Agreement shall be governed by, and
construed in accordance with, the laws of the State of Illinois, excluding any
choice of law rules which may direct the application of the law of any other
jurisdiction.

         13.06 ASSIGNMENT. Neither party may assign its rights or obligations
under this Agreement without the prior written consent of the other.

         13.07 SECTION HEADINGS. All section headings are for reference
purposes only and shall not in any way affect the meaning or interpretation of
this Agreement.

         13.08 COUNTERPARTS. This Agreement may be executed in one or more
counterparts, each of which shall be an original, but all of which taken
together shall constitute one and the same agreement.

                                      13
<PAGE>   14

         IN WITNESS WHEREOF, the duly authorized officers of the parties have
executed this Agreement as of the Effective Date.

                                             INPHARMAKON CORPORATION

                                             By:
                                                -------------------------------
                                             Title:
                                                   ----------------------------

                                             HORIZON PHARMACEUTICAL
                                             CORPORATION

                                             By:
                                                -------------------------------
                                             Title:
                                                   ----------------------------

                                       14<PAGE>   1
                                       [***] - CONFIDENTIAL TREATMENT REQUESTED

                                                                  EXHIBIT 10.10

                        CONFIDENTIAL TREATMENT REQUESTED

       Confidential Portions of this Agreement Which Have Been Redacted Are
Marked With Brackets ("[***]"). The Omitted Material Has Been Filed Separately
With The Securities And Exchange Commission.

                       EXCLUSIVE PATENT LICENSE AGREEMENT

         THIS AGREEMENT made and effective this 1st day of January, 2000, by
and between Jame Fine Chemicals, Inc., having a place of business at 100 West
Main Street, Bound Brook, New Jersey 08805 (hereinafter referred to as
"Licensor").
                                      and
         Horizon Pharmaceutical, Corporation., having a place of business at
660 Hembree Parkway, Suite 106, Roswell, Georgia 30076 (collectively
hereinafter referred to as "Licensee").

         WHEREAS, Licensor is the owner of the entire right, title and interest
in, to and under Letters Patent of the United States [****], directed to
phenylephrine tannate compositions and Letters of Patent of the United States
No. 5,663,415 granted September 2, 1997, directed to processes for producing
tannate products (said patents collectively referred to as the Licensed
Patents); and

         WHEREAS, Licensee is desirous of securing and Licensor is willing to
grant a semi-exclusive license under the Licensed Patents to use, sell and
distribute Finished Dosage Products (defined below) containing to
Chlorpheniramine Tannate;

         NOW, THEREFORE, in consideration of the covenants and obligations
hereinafter set forth to be well and truly performed, the parties hereto hereby
agree as follows:

                                  SECTION ONE
         The following definitions will apply to the respective terms as used
         throughout this Agreement.

         (a) "Net Sales" shall mean Licensee's gross invoice price of sales of
Finished Dosage Products covered by the claims of the Licensed Patents in the
Territory to third party customers after deduction of (i) cash, trade and/or
quantity discounts actually allowed; (ii) amounts repaid or credited by reason
of rejection or returns of goods, rebates (including government mandated
rebates) or because of retroactive price reductions unrelated to the sale or
pricing of another product of Licensee; and (iii) freight, postage, and duties
paid for and separately identified on invoices. A sale of a product is deemed
to have occurred upon the earliest of invoicing, shipment or transfer of title
in the product to a party other than Licensee or its affiliates or
sublicensees.

         (b) "Baseline Net Sales" shall mean Licensee's actual Net Sales for the
period January 1, 1999 through December 31, 1999.

         (c) "Annual Net Sales" shall mean Licensee's actual Net Sales for a
twelve month period January 1 to December 31 of a given year.

<PAGE>   2
                                        [***] - CONFIDENTIAL TREATMENT REQUESTED

         (d) "Territory" means the United States of America, including its
territories and possessions and Puerto Rico.

         (e) "Contract Year" shall mean the twelve (12) month period commencing
on January 1, 2000 and ending December 31, 2000 for the first Contract Year and
subsequent twelve (12) month periods commencing on the anniversary of the day
immediately following the end of the first Contract Year.

         (f) "Finished Dosage Products" means products that contain active
pharmaceutical ingredients and are in a form ready for sale to a final consumer
(including, without limitation, a liquid suspension or tablet).

                                  SECTION TWO

         (a) Licensor agrees to grant and does hereby grant to Licensee under
the Licensed Patents the exclusive right and license to use, sell and distribute
Finished Dosage Products containing Chlorpheniramine Tannate covered by the
Licensed Patents in the Territory, except only as to the license rights of
Unisource, Inc., a Colorado corporation (Unisource) and or Carter Wallace Inc.
pertaining to products that contain Chlorpheniramine Tannate and are covered by
the Licensed Patents.

         (b) Licensee agrees that it will purchase or otherwise obtain Finished
Dosage Products containing Chlorpheniramine Tannate from Unisource, Inc. and
its successors or assigns.

                                 SECTION THREE

         (a) Upon execution of this Agreement, Licensee agrees to pay to
Licensor a license fee of [***] less the [***] advance paid by Licensee to
Licensor.

         (b) Effective at the beginning of the first Contract Year, Licensee
further agrees to pay to Licensor, as royalty, [***] of its Annual Net Sales
derived by Licensee from all sales of Finished Dosage Products covered by the
Licensed Patents and made in accordance with the inventions covered thereby;
"sales" as herein employed shall mean sales of the Finished Dosage Products
covered by the Licensed Patents which are made in the United States, its
territories, possessions and Puerto Rico.

         (c)      Suspension of royalties:

                  (i) Generic. For purposes of this Section THREE (c),
"Generic" shall mean a generic to Rynatan or Tanafed but shall not include (A)
products that infringe upon the Licensed Patents or (B) products made from raw
material supplied by Licensor prior to the effective date of this Agreement.

                  (ii) Suspension. If a Generic enters the market, then, per a
determination made as of December 31 of such year of entry and December 31 of
each subsequent year of this Agreement (all of which calendar years, including
the year of entry, shall collectively be referred to as the "Calendar Years
Potentially Suspended"), Licensee's obligation for the royalty may be suspended
for one or more Calendar Years Potentially Suspended as determined as follows.
Licensee is not obligated for the royalty for any given Calendar Year
Potentially Suspended if i) the gross sales in ounces in the entirety of such
Calendar Year Potentially Suspended do not exceed the Threshold Sales
(hereinafter defined) applicable to that Calendar Year Potentially Suspended
AND ii) the Generic is available in the Territory at any time during such
Calendar Year Potentially Suspended.

<PAGE>   3
                                        [***] - CONFIDENTIAL TREATMENT REQUESTED

                  (iii) Refund of Royalties. Accordingly, if Licensee is not
obligated for the royalty in a given Calendar Year Potentially Suspended, then,
within 30 days after the end of that calendar year, Licensor shall (A) refund
royalties to Licensee so that the net effect of such refund will be that
Licensee did not pay any royalties for such calendar year and (B) pay Licensee
interest on the royalties refunded at the prime rate as of December 31 of the
calendar year for which royalties are being refunded. In the event Licensee is
not obligated for the royalties in a given calendar year, Licensee may still be
obligated for the royalty in future year(s).

                  (iv) THRESHOLDS. The Threshold Sales are as follows:
<TABLE>
<S>                                 <C>
Potential                           Threshold Sales applicable to the
                                    corresponding Calendar Year
Suspension                          Potentially Suspended
Calendar Year
                  2000              Gross sales of [***] ounces  (which is [***]
                                    of Licensee's gross sales in ounces in 1999
                                    which was [***] ounces)

                  2001              [***] of the gross sales (in ounces) in
                                    calendar years 1999 or 2000, whichever is
                                    higher

                  2002              [***] of the gross sales (in ounces) in
                                    calendar years 1999, 2000 or 2001,
                                    whichever is highest

          2003 and thereafter       [***] of the gross sales (in ounces) in
                                    calendar years 1999, 2001, 2002 or any
                                    other subsequent Calendar Year Potentially
                                    Suspended, whichever is highest
</TABLE>

                  (v)  Partial Refund of Licensing Fee: If in the year 2000,
there is a Generic available AND Licensee's Gross Sales do not exceed [***]
ounces, then Licensor will refund one half of the up-front fees paid upon
execution of this agreement.

                  (v)  Example:
2000
Based on a calculation made as of December 31, 2000, i) if Licensee's gross
sales (in ounces) for calendar 2000 (including gross sales in calendar 2000
prior to the entry of the generic) do not exceed [***] ounces, AND ii) the
Generic is available in the Territory at any time during such Calendar Year
Potentially Suspended then Licensee would not be obligated for royalties for
the entirety of calendar 2000 and would be refunded calendar 2000 royalties
accordingly; and

2001
Based on a calculation made as of December 31, 2001, i) if Licensee's gross
sales in ounces for calendar 2001 do not exceed [***] of the gross sales (in
ounces) in calendar years 1999 or 2000, whichever is highest, AND ii) the
Generic is available in the Territory at any time during such Calendar Year
Potentially Suspended then Licensee would not be obligated for royalties for
the entirety of calendar 2001 and would be refunded calendar 2001 royalties
accordingly; and

2002
Based on a calculation made as of December 31, 2002, i)
if Licensee's gross sales (in ounces) for calendar 2002 do not exceed [***] of
the gross sales (in ounces) of calendar years 1999, 2000 or 2001, whichever is
highest, AND ii) the Generic is available in the Territory at any time during
such Calendar Year Potentially Suspended then Licensee would not be obligated
for royalties for the entirety of calendar 2002 and would be refunded calendar
2002 royalties accordingly; and 2003 and thereafter

<PAGE>   4

Based on a calculation made as of December 31 of 2003 and of each year
thereafter, if i) Licensee's gross sales (in ounces) for any such calendar year
do not exceed [***] of the gross sales (in ounces) of the previous calendar
year of this Agreement in which Gross sales (in ounces) were the highest, AND
ii) the Generic is available in the Territory at any time during such Calendar
Year Potentially Suspended, then Licensee would not be obligated for royalties
for the entirety of the calendar year ending on the December 31 on which such
calculation was made, and would be refunded royalties for such calendar year
accordingly.

         (d) The term of this Agreement shall be from the date hereof to the
later of the expiration of either of the Licensed Patents or any reissue,
continuation or extension of the Licensed Patents. In the event that Licensor
becomes the owner of or has rights to patents in addition to the Licensed
Patents which additional patents pertain to the products covered by the
Licensed Patents, the term of this Agreement shall automatically extend to the
expiration of such additional patents. In any event, Licensee may continue to
renew this Agreement for five (5) year renewal periods beyond the
above-referenced patent expiration dates by providing Licensor written notice
of its intent to so renew prior to such patent expiration dates.

                                  SECTION FOUR

         It is mutually understood and agreed that the sale of compositions
covered by the Licensed Patents may be subject to approval and/or regulation by
the Food and Drug Administration or other applicable government agency and in
the event that such approval is refused or such regulation prohibits the sale
of products covered by the Licensed Patents, Licensee shall have the right to
cancel this Agreement and the license herein granted to it; in the event of
such cancellation, Licensee shall not be liable to Licensor for the payment of
any royalties hereunder or any additional license fees, as the case may be.

                                  SECTION FIVE

         All royalties provided for by this License Agreement shall be due and
payable quarterly and Licensee agrees to pay to Licensor on or before the last
day of each of the months of February, May, August and November of each
Contract Year during which this Agreement is in force, the total amount of
royalties due and payable on account of its operations under this Agreement
during the calendar quarter immediately preceding said dates.

                                  SECTION SIX

         Licensee agrees that it will render to Licensor with each such royalty
payment a written statement setting forth the total Annual Net Sales from its
royalty-bearing sales during the period covered by such statement and Licensee
agrees to keep a separate record in a suitable book or set of books provided
for the purpose, in sufficient detail to enable the royalties payable hereunder
to be determined, and further agrees that it will permit such book or set of
books to be examined by an auditor or accountant, authorized by Licensor, at
any reasonable time during business hours to the extent necessary to verify the
records and payments here provided for, it being agreed that such auditor or
accountant shall make his report to Licensor in such manner that names of
customers or other information deemed confidential by Licensee will not be
disclosed to Licensor.

                                 SECTION SEVEN

         In the event that Licensor makes or acquires any improvements or
additional patents in or relating to the inventions covered by the Licensed
Patents, such improvements and patents shall be and are hereby included as part
of the Licensed Patents upon the same terms and conditions as the said Licensed
Patents; Licensee shall not be obligated to pay to Licensor any further or

<PAGE>   5

                                          [***] CONFIDENTIAL TREATMENT REQUESTED

additional royalty or other consideration for the license to any such
additional improvements or patents. Licensee's only obligation to Licensor
shall be to continue to pay the royalty stipulated in Section Three until the
expiration of the last such patent or any reissue or extension thereof unless
otherwise provided herein.

                                 SECTION EIGHT

         Licensee shall, at its option, with the prior written consent of
Licensor, have power to institute and prosecute, at its own expense, suits for
infringement of the Licensed Patents, and, Licensor will cooperate in such
suits by furnishing such evidence, documents, and testimony as may reasonably
be required, and if required by law, Licensor will join as a party plaintiff in
such suits. All expenses in such suits will be borne entirely by Licensee and
Licensee will pay to Licensor [***] of any excess of recoveries over expenses
(including without limitation attorney fees) in such suits.

                                  SECTION NINE

         (a) Licensor warrants, that effective as of the date hereof, Licensor
and Unisource have established a business relationship (the Relationship)
whereby Unisource Inc. may purchase Chlorpheniramine Tannate and Pseudophedrine
Tannate from Jame Fine Chemicals and the Relationship shall continue for a
duration at least as long as the duration of this Agreement. Licensor further
warrants that pursuant to the Relationship, for a period of 12 months, and
thereafter it will not increase the prices for such Active Pharmaceutical
Ingredients by an amount exceeding the percentage increase in the PPI (except
that Licensor may increase such price to reflect documented increases in direct
costs which include labor, raw materials, utilities and direct overhead costs
to maintain its existing profit margin which increases will not be subject to
the PPI cap, but which increases shall have been documented to the satisfaction
of Licensee and Unisource). Licensor will decrease the prices of the Active
Pharmaceutical Ingredients to reflect decreases in the cost of such
manufacturing components. Under the terms of the Relationship, Licensor will
notify Unisource and Licensee of the change in dollars per Kg and the effective
date of any price change of each Active Pharmaceutical Ingredient utilized by
Unisource for Finished Dosage Product supplied to Licensee.

         (b) Licensor warrants that, if for any reason Licensor is unable to
supply product to meet all of the needs of Unisource, Unisource shall have the
exclusive right, along with Wallace, to receive Licensor's production of the
products covered by the Licensed Patents based on the respective amounts of
such products ordered during the preceding twelve (12) month period.

                                  SECTION TEN

         (a) Licensor represents and warrants that, as of the date hereof, it
has entered into a license agreement with Carter-Wallace, a corporation having
a place of business in Cranbury, New Jersey, in a form similar to this
Agreement and whereby Carter-Wallace has a semi-exclusive license to the
Licensed Patents as they pertain to Chlorpheniramine Tannate. (b) Licensor
warrants that in its Relationship and Licensing Agreement with Unisource, (i)
Unisource is prohibited from selling or distributing Finished Dosage Products
containing Chlorpheniramine Tannate to any person or entity other than Licensee
and (ii) Unisource does not have the right to sell Chlorpheniramine Tannate as
a stand alone active ingredient.

         (b) Licensor warrants that (a) it owns the Licensed Patents; (b) it
has the right to license the Licensed Patents to Licensee; (c) no third party
has filed any civil action against Licensor in connection with the Licensed
Patents or notified Licensor that the Licensed Patents violate such third
party's patent, trademark, copyright, or trade secret rights; (d) to the best
of Licensor's knowledge, the Licensed Patents do not infringe any third party's
copyright or patent;

<PAGE>   6

(e) it has not granted to any third party any rights in or to the Licensed
Patents that are inconsistent with any right granted to Licensee under this
License Agreement or that will adversely affect any exercise by the Licensee of
its rights granted under this License Agreement.

         (c) Licensor agrees to indemnify, defend, and hold harmless Licensee
against any losses, liabilities, claims, damages, costs, and expenses
(including reasonable attorney's fees) (the "Claims") that result from
Licensor's material breach of any of the above warranties. Licensor shall
assume all expenses with respect to the defense, settlement, adjustment, or
compromise of any Claims as to which this section requires Licensor to
indemnify, defend, or hold harmless Licensee and, upon such assumption, shall
have sole control over the defense, settlement, adjustment, or compromise of
such Claims; provided, however, that (i) Licensor shall obtain prior written
approval of Licensee, which Licensee shall not unreasonably withhold, before
entering into any settlement, adjustment, or compromise of such Claims; and
(ii) Licensee may, if it so desires, employ counsel at its own expense to
assist in the handling of such claim or undertake sole control of the defense,
settlement, adjustment, or compromise of such Claims.

                                 SECTION ELEVEN

         In the event that Licensee defaults or breaches any of the provisions
of this License Agreement or fails to account for or pay to Licensor any of the
royalties due and payable to Licensor hereunder, Licensor reserves the right to
cancel the license here granted upon sixty (60) days' written notice to
Licensee; provided, however, that if Licensee, within the sixty (60) day period
referred to, cures the said default or breach, the license herein granted shall
continue in full force and effect until the expiration of the Licensed Patents
or any reissue, continuation or extension thereof. In the event of the
termination of the license herein granted by Licensor to Licensee, Licensee
shall not be relieved of the duty and obligation to pay in full royalties
accrued and due and payable at the effective date of such termination.

                                 SECTION TWELVE

         In the event of any adjudication of bankruptcy, appointment of a
Receiver by a court of competent jurisdiction, assignment for the benefit of
creditors or levy of execution directly involving Licensee, this Agreement
shall thereupon forthwith terminate and no longer be of any further force and
effect.

                                SECTION THIRTEEN

         This Agreement shall be governed by, interpreted in accordance with,
and enforced under the laws of the State of New Jersey, U.S.A. (regardless of
its or any other jurisdiction's choice of law principles), or, as necessary,
the laws of the United States of America.

                                SECTION FOURTEEN

         This Agreement constitutes the entire agreement between the parties
hereto respecting the subject matter hereof, and supersedes and terminates all
prior agreements respecting the subject matter hereof, whether written or oral,
and may be amended only by an instrument in writing executed by both parties
hereto.

                                SECTION FIFTEEN

         (a) Indemnification by Licensee - Licensee shall indemnify and hold
Licensor harmless against all liability, damage, cost or expense (including
reasonable attorneys' fees) arising out of the promotion, distribution, sale or
use of products made using the products supplied by Licensor or its designee to
Licensee hereunder, including those resulting from any personal injury
(including death) to any person including employees, servants, or agents of
Licensee, except to the extent such liability, damage, cost or expense is
caused by the negligence, omission, failure to act, intentional malfeasance,
willful misconduct, and/or breach

<PAGE>   7

of the warranties or other obligations of Licensor under this agreement. In the
event of any claim arising under this indemnity, prompt notice of such claim
shall be given by Licensor to Licensee which shall have the right to conduct
the defense in respect thereto, but Licensor may have counsel present at its
own expense and shall be entitled to participate in the defense of any such
claim. Licensor shall cooperate with Licensee in such defense at the expense of
Licensee. No settlement of any such matter shall be made without the written
approval of Licensee and Licensor, which will not be unreasonably withheld.

         (b) Indemnification by Licensor - Licensor shall indemnify and hold
Licensee harmless against all liability, damage, cost or expense (including
reasonable attorneys' fees) arising out of any breach of this Agreement by
Licensor and/or the manufacturing, packaging and storing of products supplied
by Licensor.

                                SECTION SIXTEEN

         This Agreement and the license herein granted shall be binding upon
and inure to the benefit of each of the parties hereto, their successors and
the assigns of the entire business relating thereto of each of the parties.

                               SECTION SEVENTEEN

         If any term or provision of this Agreement is found held to be
excessive, or invalid, void or unenforceable, the offending term or revision
shall be deleted or revised to the extent necessary to be enforceable, and, if
possible, replaced by a term or provision which, so far as practicable,
achieves the legitimate aims of the parties.

                                SECTION EIGHTEEN

         Any notice or other communication given by either party hereto to the
other party relating to this Agreement shall be sent by registered or certified
mail, return receipt requested, addressed to such other party at the address
set forth above. Changes of address shall be given in the same manner as any
other notice.

         IN WITNESS WHEREOF, the parties hereto have caused this instrument to
be executed by their duly authorized representatives as of the day and year
first above written.

                                                   JAME FINE CHEMICALS, IN.

Attest:                                            By:
                                                      -------------------------
                                                   Title:
                                                         ----------------------

                                                   HORIZON PHARMACEUTICALS, INC.

Attest:                                            By:
                                                      -------------------------
                                                   Title:
                                                         ----------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00010-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00010-of-00352.parquet"}]]